Tamara Maes,
Chief Scientific Officer
Dr. Maes received her PhD in Biotechnology from the University of Ghent, Belgium. As part of the Flemish Institute of Biotechnology (VIB), her work focused on the genetic control of development. She joined the Department of Molecular Genetics at the CID/CSIC in Barcelona as part of an EU-funded project, subsequently an EMBO post-doctoral fellowship, in order to study gene transcription control mechanisms. In 2000, she founded Oryzon and is Chief Scientific Officer and Vice president of its Board of Directors. Oryzon was originally founded as a functional genomics company and used its platform to identify biomarkers in oncological and neurodegenerative disease. In 2008, the company launched its first wholly owned drug development project focusing on the epigenetic target LSD1. Today, Oryzon is one of the leaders in this field and is striving to move its drug forward in clinical development.
|
|
|
